ArticleJournal of translational medicine2025
A multi-representation deep-learning framework for accurate multicancer classification.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate multicancer classification constitutes a cornerstone of modern oncology, offering critical insights into diagnosis, therapeutic decision-making, and prognostication. Numerous existing approaches, however, remain restricted to limited cancer types and typically encode genomic information into a single representational modality. The purpose of this study was to develop and evaluate a novel framework by integrating complementary, mutation-derived features to advance cancer classification.
methodsWe present GraphVar, a multi-representation deep learning framework that integrates mutation-derived imaging and numeric genomic features for multicancer classification. GraphVar generates a spatial variant map by encoding gene-level variant categories as pixel intensities. In parallel, it constructs a numeric feature matrix capturing population allele frequencies and mutation spectra. GraphVar employs a ResNet-18 backbone to extract image-level features, a Transformer encoder to model numeric profiles, and a fusion module to integrate both modalities. Model interpretability was assessed by gradient-weighted class activation mapping (Grad-CAM), and functional relevance was validated utilizing the Kyoto Encyclopedia of Genes and Genomes (KEGG)-based pathway enrichment analysis.
resultsIn a cohort of 10,112 patients spanning 33 cancer types, GraphVar achieved a precision of 99.85%, a recall of 99.82%, an F1-score of 99.82%, and an accuracy of 99.82%. Grad-CAM highlighted the model's ability to localize gene-level molecular patterns and prioritize biologically relevant candidates. The KEGG-based pathway enrichment analysis of kidney renal clear cell carcinoma (KIRC) and breast invasive carcinoma (BRCA) samples supported the biological relevance of GraphVar-identified genes, demonstrating its capacity to capture functionally meaningful genomic signatures.
conclusionsThese findings demonstrate GraphVar as a robust and interpretable framework for multicancer classification. The model's high accuracy and its ability to identify functionally meaningful genomic signatures indicate its potential as a tool to support precision diagnostics and therapeutic strategies, warranting further translational studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.